Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Updated
Special Notice from the Department of the Army.
| Solicitation number | W911SR-26-R-HEAL |
|---|---|
| Agency | Department of the Army |
| Office | W6QK Acc-Apg |
| Notice type | Special Notice |
| Set-aside | None |
| Trade (NAICS) | Research and Development in Biotechnology (except Nanobiotechnology) (541714) |
| Product or service code | AC13 |
| Posted | Oct 21, 2026 |
| Response deadline | Not stated |
Official notice and attachments
Description
This is a continuous, open announcement with no deadline unless specifically noted. (Please note this posting was formerly the Threat Agnostic Host-Directed Therapeutics/HEALER PBA. If a white paper was previously submitted under the HEALER name, then the submission is still valid for the revised annoucement.)
Issuing Organization Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) 1. Strategic Opportunity The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) invites interested parties to enter into the CBRN Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. To maximize the efficacy of the advanced MCMs detailed in this agreement, the CPE CBRND recognizes that therapeutic intervention is intrinsically linked to rapid, and effective patient diagnosis.
Consequently, this PBA includes an integrated focus on diagnostics. This PBA establishes a unified, open, and continuous network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation CBRN medical defense solutions. The goal is to create a streamlined framework for awarding follow-on project agreements, fostering a long-term, collaborative relationship with the Government.
2. Program Vision: Building Holistic Threat Resilience The overarching goal of the CBRN MCM PBA is to develop and field a comprehensive suite of MCMs, inclusive of medical devices, drugs and biologics, to protect the warfighter within a complex and evolving CBRN threat space. This PBA is designed as an agile agreement supporting a wide range of acquisition strategies and technologies, from rapid prototyping to late-stage development and FDA licensure or clearance.
To build an integrated layered defense, the Government seeks innovative solutions across the continuum of care. This includes both pathogen or agent-based and host-based diagnostics, treatments, pre-exposure or post-exposure prophylactic countermeasures, as well as ruggedized formulations, novel drug delivery systems, and adaptable platform technologies capable of rapidly pivoting to address new and emerging threats.
This integrated approach will ensure the development of a diverse and robust portfolio of MCM capabilities, preserving the Joint Force through enhanced resilience. Examples of capabilities sought under this PBA include, but are not limited to: Host-Targeted Resilience: Development efforts focus on providing layered physiological protection and treatment by targeting critical host systems.
The Government welcomes innovative, threat-agnostic MCM candidates that enhance host resilience, including investigational drugs with multi-indication potential in civilian critical care, establishing a sustainable, long-term therapeutic pipeline. To meet the demands of far-forward operations, priority is placed on drug candidates designed for rapid employment in austere environments.
This includes formulations featuring simplified routes of administration (such as oral, intranasal, or autoinjector delivery) that can be administered without specialized medical infrastructure. Examples of sought-after mechanisms of action include, but are not limited to, neurological protection, respiratory stabilization, immune modulation, hematologic and vascular function, and cellular stress and repair pathways.
Threat-Targeted Neutralization: Complementing host resilience, efforts focus on developing broad-spectrum medical countermeasures designed to rapidly target, neutralize, and mitigate the effects of CBRN threats. The Government welcomes MCMs and adaptable platform technologies utilized for pre-exposure prophylaxis, post-exposure prophylaxis, or acute treatment. Preferred therapeutic candidates must possess robust environmental stability, eliminating reliance on cold-chain logistics, and be designed for immediate employment in austere, operational environments.
This includes formulations featuring simplified routes of administration (such as oral, intranasal, or autoinjector delivery) that can be administered without specialized medical infrastructure. Therapeutic solutions that offer rapid threat clearance, agent inactivation, disruption of lethal injury cascades, or the immediate cessation of cellular damage through highly simplified dosing regimens are highly sought after to preserve combat power and maximize return-to-duty rates.
Diagnostic Development: Host-Directed, Agent-Specific, and Pathogen Agnostic Solutions and Diagnostic Decision Support Tools: Efforts focus on developing and maturing agile, far-forward medical diagnostic capabilities. An additional area of interest is diagnostic decision support tools. The Government welcomes innovative, platform-agnostic diagnostic instrument and/or assay prototypes designed for immediate employment in austere, operational environments without reliance on specialized laboratory infrastructure.
Preferred diagnostic systems must be optimized for point-of-need use (simple, portable, battery operable or unpowered) and feature simplified sample-collection to enable employment in austere medical environments while being operated by minimally trained users. Specific areas of testing interest include pathogen specific tests, host-response tests to identify infection or physiological dysregulation due to infection, tests that assess antimicrobial resistance or susceptibility, severity of illness, and tests that diagnose toxin exposure in a timeline that supports medical intervention.
Of additional interest are test modalities that allow the earliest possible medical intervention relative to the onset of clinical symptoms. 3. Call for Collaborators: Who Should Apply?
This announcement serves as an invitation to the full spectrum of MCM developers and support organizations to join the CBRN MCM PBA partner ecosystem. A. MCM Development Collaborators: We invite submissions from developers of MCM candidates relevant to CBRN def
The description continues in the official notice.
Contracting contact
- Hunter T Robinson · [email protected]
- Alexander Mayatte · [email protected]
As published on the official notice. Ask questions in writing and before any questions deadline the notice sets.
Is your business small enough?
For NAICS 541714, a business counts as small if it has no more than 1,000 employees (SBA size standard, with exceptions in the notes). This notice is not set aside, but the size decides your small business status on it. SBA table, current as of Oct 15, 2026.
Notice history
- Aug 19, 2026: Special Notice
- Aug 19, 2026: Special Notice
- Aug 17, 2026: Special Notice
- Aug 5, 2026: Special Notice
- Jul 21, 2026: Special Notice
- Jul 21, 2026: Special Notice
- May 6, 2026: Special Notice
- Apr 23, 2026: Special Notice
Companies that win this kind of work
Federal contractors paid for research and development in biotechnology work, who also hold Army contracts (last 12 months): possible competitors, or partners to team with.
- L3 Technologies, Inc. $117.5 million in this trade
- Battelle Memorial Institute $27.0 million in this trade
- Trustees Of Boston University $10.9 million in this trade
- Fisher Bioservices Inc $10.8 million in this trade
- Applied Research Associates, Inc. $10.6 million in this trade
About the buyer
The Department of the Army awarded $83.1 billion in contracts in the last 12 months; its biggest suppliers were Lockheed Martin Corporation, Raytheon Company and The Boeing Company. See what Army is buying now.
Research and Development in Biotechnology contracts right now
There are 38 open government contract opportunities in this trade (NAICS 541714), 7 posted in the last 7 days; 45% are set aside for small businesses. The agencies buying the most are Office of Assistant Secretary for Preparedness and Response, National Institutes of Health and Defense Advanced Research Projects Agency (DARPA). Most of the work with a stated place is in District of Columbia, New Mexico and Maryland. A notice in this trade gives a median of 74 days from posting to deadline.
All open research and development in biotechnology contracts
Coming up in this trade
Planned contracts from the agencies' procurement forecasts, often months before a solicitation. Plans can change.
Recent awards in this trade
- Red Duke Strategies LLC $1.5 million · Department of Veterans Affairs · Sep 23, 2026
- Reagan-Udall Foundation For The Food And Drug Administration, Inc. $1.2 million · Defense Advanced Research Projects Agency (DARPA) · Sep 14, 2026
From the award notices agencies publish.